Cargando…

Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma

BACKGROUND: Multiple myeloma (MM) is still an incurable malignancy of plasma cells. Proteasome inhibitors (PIs) work as the backbone agent and have greatly improved the outcome in majority of newly diagnosed patients with myeloma. However, drug resistance remains the major obstacle causing treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Zhen, Wei, Xiaojing, Liu, Lanting, Sun, Hao, Fang, Teng, Wang, Lu, Li, Ying, Sui, Weiwei, Wang, Kefei, He, Yi, Zhao, Yaozhong, Huang, Wenyang, An, Gang, Meng, Fancui, Huang, Changjiang, Yu, Tengteng, Anderson, Kenneth C., Cheng, Tao, Qiu, Lugui, Hao, Mu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958548/ https://www.ncbi.nlm.nih.gov/pubmed/35344764 http://dx.doi.org/10.1016/j.ebiom.2022.103950

Ejemplares similares

P810: A NOVEL INDIRUBIN-3-MONOXIME DERIVATIVES FUNCTION AS DISRUPTORS OF PROTEOSTASIS VIA TARGETING TRIM28 IN MULTIPLE MYELOMA
por: Fang, Teng, et al.
Publicado: (2023)

An Indirubin Derivative, Indirubin-3′-Monoxime Suppresses Oral Cancer Tumorigenesis through the Downregulation of Survivin
por: Lo, Wan-Yu, et al.
Publicado: (2013)

Synthesis and antibacterial activity studies in vitro of indirubin-3′-monoximes
por: Yang, Fen-Fen, et al.
Publicado: (2022)

Increased aerobic glycolysis is important for the motility of activated VSMC and inhibited by indirubin-3′-monoxime
por: Heiss, Elke H., et al.
Publicado: (2016)

Indirubin-3′-monoxime suppresses amyloid-beta-induced apoptosis by inhibiting tau hyperphosphorylation
por: Zhang, Shu-gang, et al.
Publicado: (2016)

A Sensitive LC-MS/MS Method for the Simultaneous Determination of Two Thia-Analogous Indirubin N-Glycosides and Indirubin-3′-Monoxime in Plasma and Cell Culture Medium
por: Fischle, Alica, et al.
Publicado: (2022)

Targeting of CDK9 with indirubin 3’-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice
por: Medina-Moreno, Sandra, et al.
Publicado: (2017)

Indirubin-3′-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration
por: Blažević, Tina, et al.
Publicado: (2014)

Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment
por: Liu, Lanting, et al.
Publicado: (2020)

Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma
por: Lv, Junqiang, et al.
Publicado: (2022)

P803: CRIP1 INDUCES PIS RESISTANCE BY FORMING A COMPLEX WITH USP7/PA200 AND ENHANCING PROTEASOME ACTIVITY AND AUTOPHAGY IN MULTIPLE MYELOMA
por: Yu, Zhen, et al.
Publicado: (2023)

Multiple myeloma–derived miR‐27b‐3p facilitates tumour progression via promoting tumour cell proliferation and immunosuppressive microenvironment
por: Wei, Xiaojing, et al.
Publicado: (2023)

Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases
por: Blažević, Tina, et al.
Publicado: (2015)

P818: DNP73 PROMOTES DRUG RESISTANCE AND IMMUNE EVASION IN MULTIPLE MYELOMA BY MODULATING MYC/CD47 AXIS
por: Liu, Lanting, et al.
Publicado: (2023)

p53-Mediated Oxidative Stress Enhances Indirubin-3′-Monoxime-Induced Apoptosis in HCT116 Colon Cancer Cells by Upregulating Death Receptor 5 and TNF-Related Apoptosis-Inducing Ligand Expression
por: Dilshara, Matharage Gayani, et al.
Publicado: (2019)

Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
por: Hao, Mu, et al.
Publicado: (2011)

Viability and infectivity of Toxoplasma gondii tachyzoites exposed to Butanedione monoxime
por: Bajelan, Sara, et al.
Publicado: (2020)

Colorimetric determination of urea using diacetyl monoxime with strong acids
por: Langenfeld, Noah James, et al.
Publicado: (2021)

P838: EXOSOME MIRNAS PROFILING IN SERUM AND PROGNOSTIC EVALUATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Fang, Teng, et al.
Publicado: (2023)

Detection of recurrent cytogenetic aberrations in multiple myeloma: A comparison between MLPA and iFISH
por: Zang, Meirong, et al.
Publicado: (2015)

Four and a Half LIM Domains Protein 2 Mediates Bortezomib-Induced Osteogenic Differentiation of Mesenchymal Stem Cells in Multiple Myeloma Through p53 Signaling and β-Catenin Nuclear Enrichment
por: Xie, Zhenqing, et al.
Publicado: (2021)

Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia
por: Sun, Hao, et al.
Publicado: (2022)

MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
por: Leng, Yun, et al.
Publicado: (2016)

Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myeloma
por: Fang, Teng, et al.
Publicado: (2023)

Indirubin derivative E804 inhibits angiogenesis
por: Shin, Eun-Kyung, et al.
Publicado: (2012)

Myocyte contractility can be maintained by storing cells with the myosin ATPase inhibitor 2,3 butanedione monoxime
por: Chung, Charles S, et al.
Publicado: (2015)

Rapid Identification and Verification of Indirubin-Containing Medicinal Plants
por: Hu, Zhigang, et al.
Publicado: (2015)

Mitochondrial respiratory inhibition by 2,3‐butanedione monoxime (BDM): implications for culturing isolated mouse ventricular cardiomyocytes
por: Hall, Andrew R., et al.
Publicado: (2016)

Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
por: Yan, Yuting, et al.
Publicado: (2022)

Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis
por: Hao, Mu, et al.
Publicado: (2016)

Indirubin derivatives are potent and selective anti-Trypanosoma cruzi agents
por: Efstathiou, Antonia, et al.
Publicado: (2018)

A Mixed Micellar Formulation for the Transdermal Delivery of an Indirubin Analog
por: Seo, Seol Hwa, et al.
Publicado: (2020)

Small Molecules in the Treatment of Squamous Cell Carcinomas: Focus on Indirubins
por: Schäfer, Mirijam, et al.
Publicado: (2021)

All-Red-Light Photoswitching of Indirubin Controlled by Supramolecular Interactions
por: Thumser, Stefan, et al.
Publicado: (2021)

A tunable synthesis of indigoids: targeting indirubin through temperature
por: Shriver, James A., et al.
Publicado: (2022)

Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Combination Therapy with Indigo and Indirubin for Ulcerative Colitis via Reinforcing Intestinal Barrier Function
por: Xie, Jin, et al.
Publicado: (2023)

Indirubin inhibits cell proliferation, migration, invasion and angiogenesis in tumor-derived endothelial cells
por: Li, Zhuohong, et al.
Publicado: (2018)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j48ri4nmbc1h4bjkmptvl20097